9 Meters Biopharma, Inc. (NMTR) Stock Prices Trending Up Significantly Second Day in a Row

9 Meters Biopharma, Inc. (NMTR) stock prices were up 7.41% as of market close on April 22nd, 2021, bringing the share price up to USD$1.16. Subsequent pre-market fluctuation has seen the uptrend continue with a 5.09% increase, hiking the price per share up to USD$1.219. As of the start of the trading day on April 23rd, 2021, the stock was up 4.3104% to hit USD$1.21.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Capital Generation via Public Offering

The company announced the pricing of its public offering on March 30th, 2021, offering 30 million shares of its common stock at a price of USD$1 per share. Additional shares were offered to underwriters in a 30-day option that allowed for an additional 4.5 million shares to be sold. The gross proceeds from the offering came out to USD$31.5 million after the deduction of offering-related expenses.

Additional Funding through 2020

NMTR had closed a private placement led by Orbimed Advisors, LLC in May of 2020, which saw the generation of USD$22.5 million. December of 2020 also saw the announcement of a stock offering, led by Adage Capital Partners GP, LLC, that raised USD$32 million in net proceeds for NMTR.

NMTR Flush with Cash

The financial reports for the year ended December 31st, 2020 indicated cash and cash equivalents that amounted to roughly USD$37.9 million, a massive increase from the USD$4.6 million reported on December 31st, 2019. Over the course of 2021 so far, NMTR has generated USD$6.7 million in proceeds from the exercising of outstanding warrants in Q1 2021.

NM-002 Program

With many projects in the works, NMTR anticipates an exciting and fruitful year ahead of it. It plans to initiate the Phase 2 study of NM-002, its proprietary long-acting GLP-1 agonist, in Q2 2021. The company also anticipates a USAN/INN name in the same quarter. Topline Phase 2 results are expected in the fourth quarter of 2021, with the initiation of the Third Phase expected to be underway in the same quarter.

Optimistic Outlook for NMTR

With a significant reserve of capital that the company can use to sustain itself, and with so many promising studies and trials underway, investors are optimistic about a prosperous 2021. This confidence is reflected in the momentum of the uptrend in NMTR stock prices.


Please enter your comment!
Please enter your name here